Expert: Cancer intervention has entered the stage of precision, but there are still shortcomings in the quality control system and grassroots capabilities

China News Service, Beijing, October 28 (Zhang Jing) "Tumor interventional technology has entered a new stage of precision, individualization, and multi-technical integration, but the clinical standardized quality control system still needs to be improved, and primary diagnosis and treatment capabilities are still uneven." Recently, Teng Gaojun, an academician of the Chinese Academy of Sciences and director of the Interventional Diagnosis and Treatment Center of Zhongda Hospital Affiliated to Southeast University, said at the 12th Beijing Forum on Minimally Invasive Interventional Treatment of Tumors.

Behind this judgment is huge clinical demand. The "Analysis of Age Characteristics of Incidence and Death of Malignant Tumors in the Chinese Population in 2024" released by the National Cancer Center shows that in 2024, there will be approximately 5.1506 million new cases of malignant tumors nationwide and approximately 2.5822 million deaths.

At present, in addition to surgery, radiotherapy, and chemotherapy, interventional therapy has become one of the irreplaceable methods in comprehensive diagnosis and treatment of tumors. To put it figuratively, tumor interventional therapy is “precise attack without surgery”, that is, under the guidance of medical imaging technologies such as DSA and CT, minimally invasive therapy uses treatment devices or drugs directly applied to the tumor site through puncture catheters.

Teng Gaojun also pointed out that in the next step, we still need to make up for shortcomings in standardization and balance, and promote the discipline to move towards high-quality development by deepening academic exchanges and strengthening collaborative innovation.

Xu Binghe, academician of the Chinese Academy of Engineering and director of the National New Drug (Anti-tumor) Clinical Research Center, said that minimally invasive tumor intervention has a clear role in the precise and comprehensive diagnosis and treatment system of tumors. However, in the face of difficulties and challenges in clinical diagnosis and treatment, the industry still needs to adhere to clinical standards, strengthen multi-disciplinary cross-integration, adhere to scientific and technological innovation, pay attention to the construction of talent echelons, use multi-disciplinary joint research to solve clinical problems, and continue to improve the overall level of interventional tumor diagnosis and treatment in my country.